Why can't insulin go through a normal patch?
The outer layer of skin keeps most molecules out. Bos and Meinardi noted that "all known topical drugs used in transdermal drug-delivery systems are under 500 Dalton" and argued that "larger molecules cannot pass the corneal layer" (#31). Ordinary patches work for small, fat-soluble (lipophilic) drugs (#30). Rivastigmine and rotigotine patches are changed every 24 hours (#8, #9). Insulin is a protein, far above that cut-off.
The four kinds of microneedle
| Type | How it delivers | Status (as cited) | The catch for insulin |
|---|---|---|---|
| Hollow | A tiny needle injects liquid into the skin | Cleared device: NanoPass MicronJet600, three 600 µm needles (#32) | Needs a pump or syringe behind it |
| Coated / dissolving | Drug sits on or inside the needle and dissolves in the skin | Human trials. A dissolving measles–rubella patch was similar to injection in infants (#33) | Coated arrays usually carry under 1 mg (#34). The dose is fixed once applied. FDA did not approve Zosano's coated migraine patch in 2020, citing batch-to-batch exposure (#35) |
| Hydrogel-forming | Needles swell with skin fluid and open a path to a separate reservoir | Lab (#36) | Not tested as an insulin product |
| Glucose-responsive | Insulin is released as glucose rises, with no electronics | Animals only: mice (#39) and minipigs for over 20 hours (#40) | Hasn't reached human trials in our sources |
Do microneedles hurt less?
In a blinded study of 10 volunteers, single microneedles 480–1,450 µm long scored 5% to 40% of the pain of a standard 26-gauge needle. Length mattered most: a 3-fold increase in length raised pain 7-fold. A 10-fold increase in the number of needles raised it "just over 2-fold" (#43).
What about "smart" insulin instead of a smart patch?
Novo Nordisk's NNC2215 is an insulin built to switch on at high glucose and off at low glucose (#41). A 2026 Novo Nordisk study then found it bound more than 10 times more strongly to a paracetamol metabolite than to glucose. At a clinically relevant concentration it increased NNC2215's insulin-receptor binding in lab tests, and in pigs the metabolite changed its glucose-lowering effect; the authors say this could raise hypoglycaemia risk (#42). Making the molecule respond to glucose turns out to be hard to keep specific.
Where Micropatch fits
The concept on the home page would use a micro-pump feeding hollow microneedles or a short soft cannula. A pump can give any dose at any minute, which a coated or dissolving needle cannot. For the sensing half and the closed loop, see Is there a patch that senses glucose and doses insulin? None of this exists as a product. It is a design direction backed by the sources in the research brief.
FAQ
Insulin pumps worn as patches exist, such as Omnipod 5 and V-Go (#7, #10). They use a cannula or needle, not microneedles. Ask your care team whether one suits you.
In our sources it has only been shown in animals (#39, #40).
No. It is a research concept and not a medical device.
Sources
All numbered sources are in the research brief.
- 7Omnipod 5. research brief #7
- 8Exelon label. research brief #8
- 9Neupro PI. research brief #9
- 10V-Go review (PubMed 25904143). research brief #10
- 30Prausnitz & Langer 2008. research brief #30
- 31Bos & Meinardi 2000 (PubMed 10839713). research brief #31
- 32MicronJet600 510(k) K092746 (needle length) and FDA GUDID 17290015928011 (three 600 µm needles). research brief #32
- 33Lancet 2024 MR patch (PubMed 38697170). research brief #33
- 34Kim, Park & Prausnitz 2012. research brief #34
- 35Zosano 8-K Oct 2020. research brief #35
- 36Donnelly et al. (PubMed 23606824). research brief #36
- 39Yu et al. PNAS 2015 (PubMed 26100900). research brief #39
- 40Yu et al. Nat Biomed Eng 2020 (PubMed 32015407). research brief #40
- 41Hoeg-Jensen et al. Nature 2024 (PubMed 39415004). research brief #41
- 42Sturis et al. ACS Pharmacol Transl Sci 2026 (PubMed 42312167). research brief #42
- 43Gill et al. Clin J Pain 2008 (PubMed 18716497). research brief #43